Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
18 hedge funds and large institutions have $132K invested in Plus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
20% more funds holding
Funds holding: 15 → 18 (+3)
0.1% less ownership
Funds ownership: 0.13% → 0.03% (-0.1%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
64% less capital invested
Capital invested by funds: $369K → $132K (-$237K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$61.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$28.4K |
| 3 |
Goldman Sachs
New York
|
+$14K |
| 4 |
Millennium Management
New York
|
+$12.7K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$5.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$96K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$76.5K |
| 3 |
VF
Virtu Financial
New York
|
-$38K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$12.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$3.07K |
PSTV Hedge Fund Activity: Q2 2025 in Review
18 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q2 2025, worth a combined $132K — down 64% from $369K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PSTV positions and 5 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $61.5K. The largest seller was HRT Financial, exiting entirely with an estimated $96K sold.
- 18 institutional investors held Plus Therapeutics (PSTV) as of Q2 2025, up from 15 in Q1 2025.
- Funds reported $132K of Plus Therapeutics stock for Q2 2025, down 64% quarter-over-quarter.
- 8 funds opened new Plus Therapeutics positions in Q2 2025 and 5 closed out, a net change of +3 holders.
- The largest Plus Therapeutics buyer in Q2 2025 was Jane Street, an estimated $61.5K added.
- The largest Plus Therapeutics seller in Q2 2025 was HRT Financial, an estimated $96K sold.
Based on aggregated 13F filings for Q2 2025.